Suneel Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Suneel Gupta has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Sarita Khanna
Protagonist Therapeutics, Inc., Newark, CA, USA
4 shared publicationsFrank Valone
Protagonist Therapeutics, Inc., Newark, CA
3 shared publicationsPhillip Dinh
Protagonist Therapeutics, Inc., Newark, CA
3 shared publications- Andrew Kuykendall
Moffitt Cancer Center, Tampa, USA
2 shared publications Arturo Molina
Protagonist Therapeutics, Newark, California, United States
2 shared publications- Arturo Molina
Protagonist Therapeutics, Inc., Newark, CA
2 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (8) , 549-561.e23
Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study
- 22 May 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (8) , 549-561.e23
Open AccessRisk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study
- Open Access
- 29 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4860-4871
Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study
Patients with the primary myeloproliferative neoplasm polycythemia vera (PV) are at risk of the development of secondary malignancies, including skin cancers. This real-world, retrospective cohort study used Optum Market Clarity electronic health record (EHR) data and linked medical and pharmacy claims from 70 million patients in the US between 1 January 2007 and 31 December 2019 to assess the frequency of secondary malignancies in patients with a new or established diagnosis of PV (N=82,947 with ≥1 PV diagnosis; the final cohort for this study included 20,089 patients) and the association of these cancers with patient characteristics and PV treatment. After indexing, 36% of patients had at least one non-PV malignancy (follow-up duration, 4.3 years). The most common non-hematologic malignancies were skin cancers, including melanoma and non-melanoma skin cancer (NMSC). The incidence rate for a composite outcome of new-onset melanoma or NMSC was nearly 2-fold higher in patients who were exposed to hydroxyurea at any time than in those who were exposed to therapeutic phlebotomy alone. The strongest risk factors for occurrence of melanoma or NMSC in the observation period included older age, prior history of skin cancer, and pre-index period use of cytoreductive medications. After controlling for potential confounders, a higher likelihood of developing new-onset melanoma or NMSC was observed in patients who received ≥4 weeks of hydroxyurea exposure vs those with no hydroxyurea exposure (HR, 1.33; 95% CI, 1.17-1.50). This finding, which may have been influenced by different disease burdens among this diverse patient population, warrants further exploration.
- 29 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4860-4871
Open AccessPrevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study
Patients with the primary myeloproliferative neoplasm polycythemia vera (PV) are at risk of the development of secondary malignancies, including skin cancers. This real-world, retrospective cohort study used Optum Market Clarity electronic health record (EHR) data and linked medical and pharmacy claims from 70 million patients in the US between 1 January 2007 and 31 December 2019 to assess the frequency of secondary malignancies in patients with a new or established diagnosis of PV (N=82,947 with ≥1 PV diagnosis; the final cohort for this study included 20,089 patients) and the association of these cancers with patient characteristics and PV treatment. After indexing, 36% of patients had at least one non-PV malignancy (follow-up duration, 4.3 years). The most common non-hematologic malignancies were skin cancers, including melanoma and non-melanoma skin cancer (NMSC). The incidence rate for a composite outcome of new-onset melanoma or NMSC was nearly 2-fold higher in patients who were exposed to hydroxyurea at any time than in those who were exposed to therapeutic phlebotomy alone. The strongest risk factors for occurrence of melanoma or NMSC in the observation period included older age, prior history of skin cancer, and pre-index period use of cytoreductive medications. After controlling for potential confounders, a higher likelihood of developing new-onset melanoma or NMSC was observed in patients who received ≥4 weeks of hydroxyurea exposure vs those with no hydroxyurea exposure (HR, 1.33; 95% CI, 1.17-1.50). This finding, which may have been influenced by different disease burdens among this diverse patient population, warrants further exploration.
- Open Access
- 29 October 2025
- Published by Elsevier in Leukemia Research
- Vol. 159, 108132
Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera
- 29 October 2025
- Published by Elsevier in Leukemia Research
- Vol. 159, 108132
Open AccessRusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera
- Open Access
- 24 May 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (3) , 340-350
Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG‐300), a hepcidin mimetic, in healthy volunteers: A double‐blind first‐in‐human study
Objectives: Rusfertide is a potent peptide mimetic of hepcidin being investigated for the treatment of polycythemia vera. This randomized, placebo‐controlled, double‐blind study evaluated the safety, pharmacokinetics, and pharmacodynamics of single and repeated subcutaneous doses of an aqueous formulation of rusfertide in healthy adult males.Methods: Subjects received single doses of 1, 3, 10, 20, 40, or 80 mg rusfertide or placebo. A separate cohort of subjects received two doses of 40 mg rusfertide or placebo 1 week apart. Blood samples for pharmacokinetics and pharmacodynamics were collected, and adverse events, clinical laboratory tests, 12‐lead electrocardiograms, and vital signs were monitored.Results: Rusfertide was well tolerated. There were no serious or severe treatment‐emergent adverse events, and no patterns of clinically important adverse events, or laboratory, vital sign, or electrocardiogram abnormalities. Mean maximum rusfertide plasma concentration (Cmax) and area under the concentration–time curve increased with dose, but less than dose proportionally. Median time to Cmax was 2–4.5 h for 40 and 80 mg rusfertide and 8–24 h for lower doses. Apparent clearance and half‐life increased with dose. Single doses of rusfertide 1–80 mg were associated with dose‐dependent decreases in serum iron and transferrin‐iron saturation.Conclusions: Rusfertide was well tolerated and showed dose‐dependent pharmacokinetics and pharmacodynamics.
- 24 May 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (3) , 340-350
Open AccessPharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG‐300), a hepcidin mimetic, in healthy volunteers: A double‐blind first‐in‐human study
Objectives: Rusfertide is a potent peptide mimetic of hepcidin being investigated for the treatment of polycythemia vera. This randomized, placebo‐controlled, double‐blind study evaluated the safety, pharmacokinetics, and pharmacodynamics of single and repeated subcutaneous doses of an aqueous formulation of rusfertide in healthy adult males.Methods: Subjects received single doses of 1, 3, 10, 20, 40, or 80 mg rusfertide or placebo. A separate cohort of subjects received two doses of 40 mg rusfertide or placebo 1 week apart. Blood samples for pharmacokinetics and pharmacodynamics were collected, and adverse events, clinical laboratory tests, 12‐lead electrocardiograms, and vital signs were monitored.Results: Rusfertide was well tolerated. There were no serious or severe treatment‐emergent adverse events, and no patterns of clinically important adverse events, or laboratory, vital sign, or electrocardiogram abnormalities. Mean maximum rusfertide plasma concentration (Cmax) and area under the concentration–time curve increased with dose, but less than dose proportionally. Median time to Cmax was 2–4.5 h for 40 and 80 mg rusfertide and 8–24 h for lower doses. Apparent clearance and half‐life increased with dose. Single doses of rusfertide 1–80 mg were associated with dose‐dependent decreases in serum iron and transferrin‐iron saturation.Conclusions: Rusfertide was well tolerated and showed dose‐dependent pharmacokinetics and pharmacodynamics.
- Top Cited Papers
- 22 February 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (8) , 723-735
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis. The safety and efficacy of rusfertide in patients with phlebotomy-dependent polycythemia vera are unknown. In part 1 of the international, phase 2 REVIVE trial, we enrolled patients in a 28-week dose-finding assessment of rusfertide. Part 2 was a double-blind, randomized withdrawal period in which we assigned patients, in a 1:1 ratio, to receive rusfertide or placebo for 12 weeks. The primary efficacy end point was a response, defined by hematocrit control, absence of phlebotomy, and completion of the trial regimen during part 2. Patient-reported outcomes were assessed by means of the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) patient diary (scores range from 0 to 10, with higher scores indicating greater severity of symptoms). Seventy patients were enrolled in part 1 of the trial, and 59 were assigned to receive rusfertide (30 patients) or placebo (29 patients) in part 2. The estimated mean (±SD) number of phlebotomies per year was 8.7±2.9 during the 28 weeks before the first dose of rusfertide and 0.6±1.0 during part 1 (estimated difference, 8.1 phlebotomies per year). The mean maximum hematocrit was 44.5±2.2% during part 1 as compared with 50.0±5.8% during the 28 weeks before the first dose of rusfertide. During part 2, a response was observed in 60% of the patients who received rusfertide as compared with 17% of those who received placebo (P = 0.002). Between baseline and the end of part 1, rusfertide treatment was associated with a decrease in individual symptom scores on the MPN-SAF in patients with moderate or severe symptoms at baseline. During parts 1 and 2, grade 3 adverse events occurred in 13% of the patients, and none of the patients had a grade 4 or 5 event. Injection-site reactions of grade 1 or 2 in severity were common. In patients with polycythemia vera, rusfertide treatment was associated with a mean hematocrit of less than 45% during the 28-week dose-finding period, and the percentage of patients with a response during the 12-week randomized withdrawal period was greater with rusfertide than with placebo. (Funded by Protagonist Therapeutics; REVIVE ClinicalTrials.gov number, NCT04057040.).
- 22 February 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (8) , 723-735
Top Cited PapersRusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis. The safety and efficacy of rusfertide in patients with phlebotomy-dependent polycythemia vera are unknown. In part 1 of the international, phase 2 REVIVE trial, we enrolled patients in a 28-week dose-finding assessment of rusfertide. Part 2 was a double-blind, randomized withdrawal period in which we assigned patients, in a 1:1 ratio, to receive rusfertide or placebo for 12 weeks. The primary efficacy end point was a response, defined by hematocrit control, absence of phlebotomy, and completion of the trial regimen during part 2. Patient-reported outcomes were assessed by means of the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) patient diary (scores range from 0 to 10, with higher scores indicating greater severity of symptoms). Seventy patients were enrolled in part 1 of the trial, and 59 were assigned to receive rusfertide (30 patients) or placebo (29 patients) in part 2. The estimated mean (±SD) number of phlebotomies per year was 8.7±2.9 during the 28 weeks before the first dose of rusfertide and 0.6±1.0 during part 1 (estimated difference, 8.1 phlebotomies per year). The mean maximum hematocrit was 44.5±2.2% during part 1 as compared with 50.0±5.8% during the 28 weeks before the first dose of rusfertide. During part 2, a response was observed in 60% of the patients who received rusfertide as compared with 17% of those who received placebo (P = 0.002). Between baseline and the end of part 1, rusfertide treatment was associated with a decrease in individual symptom scores on the MPN-SAF in patients with moderate or severe symptoms at baseline. During parts 1 and 2, grade 3 adverse events occurred in 13% of the patients, and none of the patients had a grade 4 or 5 event. Injection-site reactions of grade 1 or 2 in severity were common. In patients with polycythemia vera, rusfertide treatment was associated with a mean hematocrit of less than 45% during the 28-week dose-finding period, and the percentage of patients with a response during the 12-week randomized withdrawal period was greater with rusfertide than with placebo. (Funded by Protagonist Therapeutics; REVIVE ClinicalTrials.gov number, NCT04057040.).
- Open Access
- 1 December 2021
- Published by Elsevier in Gastroenterology
- Vol. 161 (6) , 1853-1864.e10
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis
- 1 December 2021
- Published by Elsevier in Gastroenterology
- Vol. 161 (6) , 1853-1864.e10
Open AccessPTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis
- Open Access
- 22 October 2018
- Published by Wiley in Parkinson's Disease
- Vol. 2018, 1-8
Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations
Background. IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD). Following an initial peak at about one hour, plasma LD concentrations are maintained for about 4-5 hours. Objective. To present dosing factors that may affect the successful conversion to ER CD-LD from other LD formulations. Methods. Two-phase 3 studies of ER CD-LD vs. immediate-release (IR) CD-LD (ADVANCE-PD) and vs. CD-LD + entacapone (CLE; ASCEND-PD) in subjects with advanced PD included a 6-week, open-label conversion to ER CD-LD prior to treatment randomization. The “converted” daily LD dose ratio and dose frequency for ER CD-LD were compared to the prior LD treatment regimens at study entry. Results. The average daily LD dose ratio at the end of dose conversion to ER CD-LD was approximately 2.1 for IR CD-LD and 2.8 for CLE. The final dose ratios tended to be slightly higher for participants taking lower LD doses at study entry but independent of dose frequency. ER CD-LD dose frequency increased with increasing LD dose and dose frequency at study entry. Participants on higher baseline LD doses ≥800 mg and dose frequencies ≥6 tended to have higher rates of discontinuation during conversion to ER CD-LD. Conclusions. Converting participants from other LD formulations to ER CD-LD is based on their current LD regimen. For the most common daily doses (≤1250 mg) and dose frequencies (<7) of LD, final mean dose ratios were within tight ranges of 2.1 to 2.4 for IR CD-LD (ADVANCE-PD) and 2.4 to 2.8 for CLE (ASCEND-PD) and were generally independent of the LD dosing frequency at study entry. These trials are registered with NCT00974974, NCT01130493.
- 22 October 2018
- Published by Wiley in Parkinson's Disease
- Vol. 2018, 1-8
Open AccessDosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations
Background. IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD). Following an initial peak at about one hour, plasma LD concentrations are maintained for about 4-5 hours. Objective. To present dosing factors that may affect the successful conversion to ER CD-LD from other LD formulations. Methods. Two-phase 3 studies of ER CD-LD vs. immediate-release (IR) CD-LD (ADVANCE-PD) and vs. CD-LD + entacapone (CLE; ASCEND-PD) in subjects with advanced PD included a 6-week, open-label conversion to ER CD-LD prior to treatment randomization. The “converted” daily LD dose ratio and dose frequency for ER CD-LD were compared to the prior LD treatment regimens at study entry. Results. The average daily LD dose ratio at the end of dose conversion to ER CD-LD was approximately 2.1 for IR CD-LD and 2.8 for CLE. The final dose ratios tended to be slightly higher for participants taking lower LD doses at study entry but independent of dose frequency. ER CD-LD dose frequency increased with increasing LD dose and dose frequency at study entry. Participants on higher baseline LD doses ≥800 mg and dose frequencies ≥6 tended to have higher rates of discontinuation during conversion to ER CD-LD. Conclusions. Converting participants from other LD formulations to ER CD-LD is based on their current LD regimen. For the most common daily doses (≤1250 mg) and dose frequencies (<7) of LD, final mean dose ratios were within tight ranges of 2.1 to 2.4 for IR CD-LD (ADVANCE-PD) and 2.4 to 2.8 for CLE (ASCEND-PD) and were generally independent of the LD dosing frequency at study entry. These trials are registered with NCT00974974, NCT01130493.
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Dosing Patterns During Conversion to IPX066, Extended-Release Carbidopa-Levodopa, from Other Carbidopa-Levodopa Formulations in Advanced Parkinson’s Disease Patients (P2.338)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Dosing Patterns During Conversion to IPX066, Extended-Release Carbidopa-Levodopa, from Other Carbidopa-Levodopa Formulations in Advanced Parkinson’s Disease Patients (P2.338)
- 6 April 2004
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 25 (5) , 219-225
Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions
Aims—To use a nonparametric approach involving longitudinal splines to model the baseline blood pressure profile and investigate the impact of this modelling on the pharmacodynamic analysis for verapamil in patients with angina or hypertension. Methods—Dose ranging studies were conducted in patients with hypertension and with angina. Subjects received doses of 120, 180, 360 or 540mg racemic verapamil. Pharmacodynamic data were created by subtracting the (systolic) blood pressure following active drug from the placebo response, either by direct subtraction or after modelling the baseline with a longitudinal spline model fitted to the placebo data by nonlinear mixed effects modelling. An Emax model was then used to describe the relationship between change in blood pressure and (R‐)verapamil plasma concentration. Results—The maximum decrease in systolic blood pressure was found to be 57.6 (±26.1) mm and the C50 was 420 (±349) µg/l for the data obtained by direct subtraction of the placebo data. Similar results were obtained when a cubic spline model was used to describe each individual's placebo response. However, the use of a population spline model only allowed a linear pharmacodynamic model to be fitted to the resulting data. Sparse data were created by randomly removing 66% of the data from the placebo and active phases. The population spline model gave very similar parameter estimates for the linear model applied to the sparse data to those obtained from the complete data set. Conclusions—The use of a longitudinal spline model together with nonlinear mixed effects modelling to account for baseline blood pressure response can be very powerful in a sparse data environment. Copyright © 2004 John Wiley & Sons, Ltd.
- 6 April 2004
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 25 (5) , 219-225
Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions
Aims—To use a nonparametric approach involving longitudinal splines to model the baseline blood pressure profile and investigate the impact of this modelling on the pharmacodynamic analysis for verapamil in patients with angina or hypertension. Methods—Dose ranging studies were conducted in patients with hypertension and with angina. Subjects received doses of 120, 180, 360 or 540mg racemic verapamil. Pharmacodynamic data were created by subtracting the (systolic) blood pressure following active drug from the placebo response, either by direct subtraction or after modelling the baseline with a longitudinal spline model fitted to the placebo data by nonlinear mixed effects modelling. An Emax model was then used to describe the relationship between change in blood pressure and (R‐)verapamil plasma concentration. Results—The maximum decrease in systolic blood pressure was found to be 57.6 (±26.1) mm and the C50 was 420 (±349) µg/l for the data obtained by direct subtraction of the placebo data. Similar results were obtained when a cubic spline model was used to describe each individual's placebo response. However, the use of a population spline model only allowed a linear pharmacodynamic model to be fitted to the resulting data. Sparse data were created by randomly removing 66% of the data from the placebo and active phases. The population spline model gave very similar parameter estimates for the linear model applied to the sparse data to those obtained from the complete data set. Conclusions—The use of a longitudinal spline model together with nonlinear mixed effects modelling to account for baseline blood pressure response can be very powerful in a sparse data environment. Copyright © 2004 John Wiley & Sons, Ltd.
- 1 January 1996
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 36 (1) , 25-34
Simultaneous First‐Order and Capacity‐Limited Elimination Kinetics After Oral Administration of Verapamil
In this study of the relationship between dose and plasma concentration of verapamil, controlled‐release verapamil in doses of 120 mg, 180 mg, 360 mg, and 540 mg were examined. The 48 study subjects received verapamil daily during each of the 4 sequential 5‐day dosing segments. Blood samples were collected frequently to obtain first‐dose and steady‐state (fifth dose) concentration profiles of verapamil. Plasma concentrations of R‐and S‐verapamil and R‐ and S‐norverapamil were measured by stereospecific assay. Statistical comparisons of pharmacokinetic parameters and mean differences between doses were performed with analysis of variance models. At steady state, area under the concentration—time curve (AUC) values for R‐ and S‐verapamil at both the 120‐mg and 180‐mg doses were about 1.5 times higher than the corresponding first‐dose values. After both first and fifth doses, pharmacokinetic parameters for all four analytes were dose proportional between the 120‐mg and 180‐mg doses. A dose‐proportional relationship also was found between the 360‐mg and 540‐mg dose levels. However, nonlinearity was found between the 180‐mg dose and higher doses, suggesting saturable metabolic pathways. The dose‐proportional relationship between the 360‐mg and 540‐mg doses suggests that other first‐order metabolic pathways become dominant. Although results from this study are partially consistent with previously reported nonlinear verapamil kinetics, this is the first clinical study to demonstrate a dose‐proportional relationship for verapamil at both low and high input rates (mg/hr). In addition, first‐order disposition pathways of verapamil are probably nonexistent at medium input rates and become dominant at higher input rates.
- 1 January 1996
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 36 (1) , 25-34
Simultaneous First‐Order and Capacity‐Limited Elimination Kinetics After Oral Administration of Verapamil
In this study of the relationship between dose and plasma concentration of verapamil, controlled‐release verapamil in doses of 120 mg, 180 mg, 360 mg, and 540 mg were examined. The 48 study subjects received verapamil daily during each of the 4 sequential 5‐day dosing segments. Blood samples were collected frequently to obtain first‐dose and steady‐state (fifth dose) concentration profiles of verapamil. Plasma concentrations of R‐and S‐verapamil and R‐ and S‐norverapamil were measured by stereospecific assay. Statistical comparisons of pharmacokinetic parameters and mean differences between doses were performed with analysis of variance models. At steady state, area under the concentration—time curve (AUC) values for R‐ and S‐verapamil at both the 120‐mg and 180‐mg doses were about 1.5 times higher than the corresponding first‐dose values. After both first and fifth doses, pharmacokinetic parameters for all four analytes were dose proportional between the 120‐mg and 180‐mg doses. A dose‐proportional relationship also was found between the 360‐mg and 540‐mg dose levels. However, nonlinearity was found between the 180‐mg dose and higher doses, suggesting saturable metabolic pathways. The dose‐proportional relationship between the 360‐mg and 540‐mg doses suggests that other first‐order metabolic pathways become dominant. Although results from this study are partially consistent with previously reported nonlinear verapamil kinetics, this is the first clinical study to demonstrate a dose‐proportional relationship for verapamil at both low and high input rates (mg/hr). In addition, first‐order disposition pathways of verapamil are probably nonexistent at medium input rates and become dominant at higher input rates.